Har­vard schol­ars call to elim­i­nate or­phan drug ex­emp­tion in IRA to save Medicare more

While bio­phar­ma com­pa­nies are call­ing foul over the fact that block­buster drugs with mul­ti­ple or­phan des­ig­na­tions re­main el­i­gi­ble for gov­ern­ment price ne­go­ti­a­tions un­der the In­fla­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER